Malaria parasite clearance: what are we really measuring?

Simple item page
dc.contributor.authorKhoury, D.S.
dc.contributor.authorZaloumis, S.G.
dc.contributor.authorGrigg, M.J.
dc.contributor.authorHaque, A.
dc.contributor.authorDavenport, M.P.
dc.contributor.authorCromer, D.
dc.contributor.authorRebelo, M.
dc.contributor.authorCao, P.
dc.contributor.authorMcCaw, J.M.
dc.contributor.authorSimpson, J.A.
dc.contributor.authorFlegg, J.A.
dc.contributor.authorWilson, D.W.
dc.contributor.authorAnstey, N.M.
dc.contributor.authorMcCarthy, J.S.
dc.date.issued2020
dc.description.abstractAntimalarial drugs are vital for treating malaria and controlling transmission. Measuring drug efficacy in the field requires large clinical trials and thus we have identified proxy measures of drug efficacy such as the parasite clearance curve. This is often assumed to measure the rate of drug activity against parasites and is used to predict optimal treatment regimens required to completely clear a blood-stage infection. We discuss evidence that the clearance curve is not measuring the rate of drug killing. This has major implications for how we assess optimal treatment regimens, as well as how we prioritise new drugs in the drug development pipeline.
dc.description.statementofresponsibilityDavid S.Khoury, Sophie G.Zaloumis, Matthew J.Grigg, Ashraful Haque, Miles P.Davenport, The Interdisciplinary Approaches to Malaria Consortium
dc.identifier.citationTrends in Parasitology, 2020; 36(5):413-426
dc.identifier.doi10.1016/j.pt.2020.02.005
dc.identifier.issn1471-4922
dc.identifier.issn1471-5007
dc.identifier.orcidWilson, D.W. [0000-0002-5073-1405]
dc.identifier.urihttps://hdl.handle.net/2440/134069
dc.language.isoen
dc.publisherElsevier
dc.relation.granthttp://purl.org/au-research/grants/arc/DP120100064
dc.relation.granthttp://purl.org/au-research/grants/arc/DP180103875
dc.relation.granthttp://purl.org/au-research/grants/arc/DE170100785
dc.relation.granthttp://purl.org/au-research/grants/arc/DP170103076
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1104975
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1143974
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1082022
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1126399
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1028641
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1028643
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1141921
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1100394
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1132975
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1135820,
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1138860
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1080001
dc.rights© 2020 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.pt.2020.02.005
dc.subjectMalaria; drug development; drug efficacy; parasite clearance
dc.subject.meshHumans
dc.subject.meshPlasmodium falciparum
dc.subject.meshParasitemia
dc.subject.meshMalaria, Falciparum
dc.subject.meshAntimalarials
dc.subject.meshTreatment Outcome
dc.titleMalaria parasite clearance: what are we really measuring?
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Environment Institute publications